Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 72 of 370 for:    LENALIDOMIDE AND Dexamethasone

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04009109
Recruitment Status : Not yet recruiting
First Posted : July 4, 2019
Last Update Posted : July 31, 2019
Sponsor:
Collaborators:
Janssen Scientific Affairs, LLC
Celgene Corporation
Takeda
Information provided by (Responsible Party):
Alliance Foundation Trials, LLC.

Brief Summary:

A randomized Phase II clinical trial will be conducted to assess the impact on progression free survival (PFS) with the addition of ixazomib and daratumumab to lenalidomide as a maintenance treatment following induction with lenalidomide, ixazomib, dexamethasone, and daratumumab.

Patients will be randomized to either:

Arm A: 12 cycles of lenalidomide, ixazomib, daratumumab, and dexamethasone followed by lenalidomide until disease progression or unacceptable toxicity or a maximum of 2 years of maintenance therapy.

Arm B: 12 cycles of lenalidomide, ixazomib, daratumumab and dexamethasone, followed by lenalidomide, ixazomib, and daratumumab until disease progression or unacceptable toxicity or a maximum of 2 years maintenance therapy.


Condition or disease Intervention/treatment Phase
Myeloma, Multiple Drug: Lenalidomide Drug: Ixazomib Drug: Daratumumab Injection Drug: Dexamethasone Phase 2

Detailed Description:

Induction Phase: 28-day treatment cycle for 12 cycles:

  • Lenalidomide 15 mg PO QD on Days 1-21
  • Ixazomib 4 mg PO on Days 1, 8, 15
  • Daratumumab 16 mg/kg IV Q1W week for 8 weeks, then Q2W weeks for 16 weeks, thereafter Q4W weeks
  • Dexamethasone 20 mg PO will be administered day of and day after all doses of daratumumab and ixazomib (Days 1, 2, 8, 9, 15, and 16). The dexamethasone 20 mg PO oral or IV dose administered as a pre-infusion medication on daratumumab infusion days (Days 1, 8, 15, 22) replaces the oral dexamethasone dose for that day.

Maintenance Phase: 28-day treatment cycle until progression or excessive toxicity or a maximum of 2 years of maintenance treatment:

Arm A

  • Lenalidomide 10 mg PO QD on Days 1-21 Arm B
  • Lenalidomide 10 mg PO QD on Days 1-21
  • Ixazomib 3 mg (or last tolerated dose from the induction phase) PO on Days 1, 8, and 15
  • Daratumumab 16 mg/kg IV on Day 1

In the maintenance phase, dexamethasone, 20 mg PO orally or IV will be administered to patients as a pre-infusion medication prior to daratumumab dosing. When dexamethasone is reduced to 20 mg/week and is given as pre-infusion medication, patients may receive low-dose methylprednisolone (≤20 mg) orally (or equivalent in accordance with local standards) for the prevention of delayed IRRs as clinically indicated.

If the investigator wishes to continue the maintenance regimen at the end of the 2 years maintenance treatment, patients may continue current maintenance as per standard of care.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 188 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
Estimated Study Start Date : October 1, 2019
Estimated Primary Completion Date : October 1, 2024
Estimated Study Completion Date : December 31, 2024


Arm Intervention/treatment
Experimental: Lenalidomide
12 cycles of lenalidomide, ixazomib, daratumumab, and dexamethasone followed by lenalidomide until disease progression or unacceptable toxicity or a maximum of 2 years of maintenance therapy.
Drug: Lenalidomide
Induction and Maintenance
Other Name: Revlimid

Drug: Ixazomib
Induction and Only Maintenance Arm B
Other Name: Ninlaro

Drug: Daratumumab Injection
Induction and Only Maintenance Arm B
Other Name: Darzalex

Drug: Dexamethasone
Induction and Only Maintenance Arm B
Other Name: Ozurdex

Experimental: Lenalidomide, Ixazomib, Daratumumab, and Dexamethasone
12 cycles of lenalidomide, ixazomib, dexamethasone, and daratumumab followed by lenalidomide, ixazomib, and daratumumab until disease progression or unacceptable toxicity or a maximum of 2 year maintenance therapy.
Drug: Lenalidomide
Induction and Maintenance
Other Name: Revlimid

Drug: Ixazomib
Induction and Only Maintenance Arm B
Other Name: Ninlaro

Drug: Daratumumab Injection
Induction and Only Maintenance Arm B
Other Name: Darzalex

Drug: Dexamethasone
Induction and Only Maintenance Arm B
Other Name: Ozurdex




Primary Outcome Measures :
  1. Impact of Study Treatment on Progression Free Survival (PFS) [ Time Frame: 5 Years ]
    Time interval between registration and progression or death.


Secondary Outcome Measures :
  1. Minimal Residual Disease (MRD) [ Time Frame: 5 Years ]
    Minimal residual disease (MRD) negativity in the blood and marrow will be determined using the IMWG criteria.

  2. Toxicity Profile of Treatment Arm Based on Patient Response [ Time Frame: 5 Years ]
    Evaluation of incidence and severity of adverse events by summaries of toxicity data/contingency tables.

  3. Overall Response Rate (ORR) [ Time Frame: 5 Years ]
    Proportion of patients with reduction in tumor burden of a predefined amount.

  4. Overall Survival (OS) [ Time Frame: 5 Years ]
    Time from registration to death due to any cause.

  5. Quality of Life with the EQ 5D 5L Questionnaire [ Time Frame: 5 Years ]
    Consists of 2 parts: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

  6. Quality of Life with the EORTC QLQ-MY20 Questionnaire [ Time Frame: 5 Years ]
    The EORTC QLQ-MY20 module was developed as an addition to the QLQ-C30 for use specifically in MM. It has 4 domains (disease symptoms, side effects of treatment, body image, future perspectives). Scores range from 0 to 100; good HRQoL is indicated by high scores for future perspective and body image, and low scores for disease symptoms and side effects of treatment.

  7. Quality of Life with the EORTC QLQ-C30 Questionnaire [ Time Frame: 5 Years ]
    The EORTC QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status/QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.

  8. Rate of Adherence to Lenalidomide and Ixazomib [ Time Frame: 5 Years ]
    All patients who have begun treatment will be included in the estimate of adherence rate to lenalidomide and the estimate of the adherence rate to ixazomib.

  9. Alliance Geriatric Assessment with IMWG Fragility Score [ Time Frame: 5 Years ]
    To describe functional status, comorbidity, psychological state, social activity, social support, chemotherapy toxicity, and nutrition using the geriatric assessment tool.


Other Outcome Measures:
  1. Changes in Body Composition After Induction Therapy [ Time Frame: 5 Years ]
    Fat and lean mass will be measured using dual energy X-ray absorptiometry (DXA previously DEXA).

  2. Circulating MM cells and circulating DNA through DNA sequencing [ Time Frame: 5 Years ]
    Blood samples will be collected to study DNA of normal and any potential tumor cells in blood. Further assessment of the genes, the RNA, and the proteins that are found in MM cells as well as in normal, noncancerous cells will be done.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient must be at least 18 years of age.
  2. Documentation of a multiple myeloma-defining event (MDE):

    Clonal bone marrow plasma cells ≥10% or biopsy-proven bony or extramedullary plasmacytoma and any one or more of the following CRAB features and myeloma-defining events:

    Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically:

    • Hypercalcemia: serum calcium >0.25 mmol/L (>1 mg/dL) higher than the upper limit of normal (ULN) or >2.75 mmol/L (>11 mg/dL).
    • Renal insufficiency: creatinine clearance <40 mL per minute or serum creatinine >177 mol/L (>2 mg/dL).
    • Anemia: hemoglobin value of >20 g/L below the lowest limit of normal, or a hemoglobin value <100 g/L.
    • Bone lesions: one or more osteolytic lesion on skeletal radiography, CT, or PET/CT. If bone marrow has <10% clonal plasma cells, more than one bone lesion is required to distinguish from solitary plasmacytoma with minimal marrow involvement.

    Any one or more of the following biomarkers of malignancy (MDEs):

    • Sixty percent (60%) or greater clonal plasma cells on bone marrow examination.
    • Serum involved/uninvolved free light chain ratio of 100 or greater, provided the absolute level of the involved light chain is at least 100 mg/L (a patient's involved free light chain, either kappa or lambda, is the one that is above the normal reference range; the uninvolved free light chain is the one that is typically in, or below, the normal range).
    • More than one focal lesion on MRI that is at least 5 mm or greater in size.
  3. Newly diagnosed and not considered candidate for high-dose chemotherapy with stem cell transplant due to:

    • Being age ≥75 years, OR
    • In patients <75 years: presence of important comorbid condition(s) likely to have a negative impact on tolerability of high dose chemotherapy with stem cell transplantation (ASCT) and/or Investigator's discretion due to concern regarding acute and long-term toxicity.
    • Including dysfunction (such as cardiac, pulmonary, hepatic, GI, renal) and limitations in mental/mobility and logistical function precluding safe use of ASCT as a treatment modality.
  4. Patient must have an ECOG performance status score of 0, 1, or 2.
  5. Patient must have adequate pretreatment clinical laboratory values meeting the following criteria ≤14 days of initial study drug administration:

    • hemoglobin ≥7.5 g/dL (prior red blood cell transfusion or recombinant human erythropoietin use is permitted).
    • absolute neutrophil count (ANC) ≥1.0x109/L (granulocyte colony stimulating factor (GCSF use is permitted).
    • platelet count ≥75x109/L for patients in whom <50% of bone marrow nucleated cells are plasma cells; otherwise, platelet count >50×109/L (transfusions are not permitted to achieve this minimum platelet count).
    • aspartate aminotransferase (AST) ≤3xULN.
    • alanine aminotransferase (ALT) ≤3xULN.
    • total bilirubin ≤1.5xULN, except in patients with congenital bilirubinemia, such as Gilbert syndrome (direct bilirubin ≤2.0xULN).
    • creatinine clearance (CrCl) ≥30 mL/min. (Creatinine clearance may be calculated using the Cockcroft-Gault formula provided in corrected serum calcium ≤14 mg/dL (≤3.5 mmol/L); or free ionized calcium <6.5 mg/dL (<1.6 mmol/L).
  6. Women of childbearing potential (WOCBP) must commit to either abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control simultaneously. This includes one highly effective form of contraception (tubal ligation, intrauterine device [IUD], hormonal [birth control pills, injections, hormonal patches, vaginal rings or implants] or partner's vasectomy) and one additional effective contraceptive method (male latex or synthetic condom, diaphragm, or cervical cap). Contraception must begin 4 weeks prior to initial dosing. Reliable contraception is indicated even where there has been a history of infertility, unless due to hysterectomy or bilateral oophorectomy.
  7. A man who is sexually active with a WOCBP must agree to use a latex or synthetic condom, even if they had a successful vasectomy. All men must also not donate sperm during the study, for 4 weeks after the last dose of lenalidomide, and for 4 months after the last dose of daratumumab.
  8. A WOCBP must have 2 negative serum or urine pregnancy tests first within 10 to 14 days prior to initial dosing.
  9. All study patients must be registered into the mandatory Revlimid REMS® program and be willing and able to comply with the requirements of the REMS® program.
  10. Females of reproductive potential must agree to adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program.
  11. Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  1. Prior history of primary amyloidosis, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma (MM). Note: Monoclonal gammopathy of undetermined significance is defined by presence of serum M-protein <3 g/dL; absence of lytic bone lesions, anemia, hypercalcemia, and renal insufficiency related to the M-protein; and (if determined) proportion of plasma cells in the bone marrow of 10% or less. Smoldering multiple myeloma is defined as asymptomatic MM with absence of related organ or tissue impairment end organ damage
  2. Prior history of Waldenström's disease, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions.
  3. Prior or current systemic therapy or stem cell transplantation (SCT) for MM, with the exception of an emergency use of a short course (equivalent of dexamethasone 40 mg/day for a maximum 4 days) of corticosteroids before initial dosing.
  4. History of malignancy (other than MM) within 5 years prior to screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix).
  5. Radiation therapy ≤14 days prior to screening.
  6. Plasmapheresis ≤28 days prior to screening.
  7. Exhibiting clinical signs of meningeal involvement of MM ≤28 days prior to screening.
  8. Known chronic obstructive pulmonary disease (COPD) (defined as a forced expiratory volume [FEV] in 1 second <60% of predicted normal), persistent asthma, or a history of asthma ≤ 2 years prior to screening (intermittent asthma is allowed). Note: Patients with known or suspected COPD or asthma must have a FEV1 test within 28 days prior to screening.
  9. Patient has history or evidence of unstable/uncontrolled medical or psychiatric disorder, condition or disease (e.g., active systemic infection, uncontrolled diabetes, acute diffuse infiltrative pulmonary disease) that is likely to interfere with the study procedures or results, or that in the opinion of the investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion.
  10. Clinically significant cardiac disease, including:

    • myocardial infarction ≤1 year prior to screening, or an unstable or uncontrolled disease/condition related to or affecting cardiac function (eg, unstable angina, congestive heart failure, New York Heart Association Class III-IV).
    • uncontrolled cardiac arrhythmia (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] Version 5.0 Grade ≥2) or clinically significant ECG abnormalities;
    • 12-lead ECG performed ≤28 days prior to screening showing a baseline QT interval as corrected by Fridericia's formula (QTcF) >470 msec.
  11. Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies, or human proteins, or their excipients (refer to respective package inserts or Investigator's Brochure) or known sensitivity to mammalian-derived products.
  12. History of plasma cell leukemia (by WHO criterion: ≥20% of cells in the peripheral blood with an absolute plasma cell count of more than 2×109/L) or POEMS syndrome (ie, polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
  13. Patient is:

    • seropositive for human immunodeficiency virus (HIV)
    • seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.
    • seropositive for hepatitis C (except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy).
  14. A woman who is pregnant, or breast-feeding, or planning to become pregnant during the study period or a man who plans to father a child during the study period. See Section 12.8 for further details.
  15. Major surgery ≤14 days prior to screening or has not fully recovered from surgery, or has surgery planned during the time the patient is expected to participate in the study. Note: Kyphoplasty or vertebroplasty is not considered major surgery.
  16. Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device ≤28 days prior to initial dosing or is currently enrolled in an interventional investigational study.
  17. Contraindications to required protocol prophylaxis for deep vein thrombosis and pulmonary embolism.
  18. Peripheral neuropathy Grade 2 or severe ≤28 days prior to screening.
  19. Systemic treatment with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. John's wort ≤14 days prior to screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04009109


Contacts
Layout table for location contacts
Contact: Joseph B. Gannon Jr. 617-525-8177 info@alliancefoundationtrials.org

Sponsors and Collaborators
Alliance Foundation Trials, LLC.
Janssen Scientific Affairs, LLC
Celgene Corporation
Takeda
Investigators
Layout table for investigator information
Principal Investigator: Monica Bertagnolli, MD Alliance Foundation Trials, LLC.
Study Chair: Elizabeth K. O'Donnell, MD Massachusetts General Hospital
Study Chair: Jacob P. Laubach, MD Dana-Farber Cancer Institute

Publications:

Layout table for additonal information
Responsible Party: Alliance Foundation Trials, LLC.
ClinicalTrials.gov Identifier: NCT04009109     History of Changes
Other Study ID Numbers: AFT-41
First Posted: July 4, 2019    Key Record Dates
Last Update Posted: July 31, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dexamethasone
Dexamethasone acetate
Lenalidomide
BB 1101
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Ixazomib
Daratumumab
Antibodies, Monoclonal
Glycine
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones